Silvi Joins Partnership to Develop AI Solutions for Evidence-Based Medicine

In the fields of clinical medicine and healthcare, systematic reviews are conducted to synthesize and summarize all available evidence on a given clinical question. In addition, systematic reviews help researchers identify research gaps. From a public healthy perspective, systematic reviews are crucial because they play a central role in evidence-based decision-making by healthcare professionals. Evidence distilled through rigorous systematic reviews ensure that patients receive medicine and treatments that are not only safe but also effective.

Given the overwhelming volume of research and the rigorous scientific standards required of a systematic review, these projects traditionally take considerable time and effort. Recent advances in the field of artificial intelligence (AI) have, however, made it possible to optimize the process.

Since there is an immense potential to revolutionize the systematic review process with AI, Silvi is collaborating with the Danish Medicines Council (Medicinrådet) in the autumn of 2025 to develop AI-powered solutions to make the review process time-efficient without losing out on scientific rigor and transparency. Silvi is developing and testing several AI-powered features that will help researchers screen thousands of studies, extract relevant data from them, and to synthesize available scientific evidence in a much more timely and cost-effective manner.

Officially called Evidence in an AI age (EVA), the project is funded by the Innovations Fund Denmark and will last two years (2025-2027). In addition to collaborating with the

Danish Medicines Council, Silvi is partnering with universities such as the University of Southern Denmark and Ghent University, Belgium and pharmaceutical companies such as Johnson & Johnson, Leo Pharma, and KIOX pharma. Silvi is also partnering with Denmark’s leading experts in AI and life sciences including Anders Søgaard, professor of AI and natural language processing at the University of Copenhagen, and Anton Pottegaard, professor of pharmacoepidemiology at the University of Southern Denmark.

Partnerships with academic institutions, collaborations with pharmaceutical companies, and cooperation with a governmental agency like the Danish Medicines Council will ensure that the AI solutions Silvi develops are time efficient as well as scientifically rigorous.